Skip to main content

Summit Medical Group Is Among First in U.S. to Offer the Duette Study:
A Clinical Research Study for Women with Relapsed Ovarian Cancer


Ovarian cancer is the second most common gynecologic cancer in the United States and causes more deaths than any other cancer of the female reproductive system.

Despite significant advances in the management of women with advanced stage ovarian cancer, there are still many pressing questions.  PARP inhibitors (poly-ADP ribose polymerase) are a promising new area in cancer treatment and have significantly improved survival in women diagnosed with ovarian cancer.  Established as a treatment for women with recurrent disease, PARP inhibitors are now being used in the setting of maintenance therapy for women who are either newly diagnosed, have completed chemotherapy, or those who have had recurrent disease and are now in their second remission. While these agents have provided significant benefit in prolonging survival, it remains unknown how women with recurrent disease should be treated. 

An exciting new study called the DUETTE Study is offered at Summit Medical Group to investigate the effectiveness of a second maintenance treatment in platinum-sensitive relapsed patients who have previously received PARP inhibitor treatment. Led by principal investigator Darlene Gibbon, MD, Medical Director of Gynecologic Oncology at Summit Medical Group, the study aims to determine complete response, partial response, or disease stability in women with relapsed ovarian cancer.

Learn more:

       Michelle Mackenzie, RN, OCN, CCRC
       Summit Medical Group